CJC-1295 Dosage Protocol: DAC vs No-DAC, Loading, and Maintenance (2026 Guide)

CJC-1295 Dosage: What the Clinical Data Actually Says

CJC-1295 dosage depends entirely on which variant you're using. The DAC version requires once-weekly subcutaneous injections of 2 mg due to its 5.8–8.1-day half-life, while the no-DAC variant demands daily dosing at 100–300 mcg to maintain pulsatile growth hormone release. Getting this wrong negates the compound's entire pharmacokinetic advantage.

Most dosage guides collapse CJC-1295 DAC and CJC-1295 no-DAC into a single protocol. That's a fundamental error. These are pharmacologically distinct molecules with different half-lives, different GH secretion patterns, and different stacking requirements. This guide breaks each variant down separately, covers loading versus maintenance phases, and maps the clinical evidence behind every number.

The DAC Modification: Why It Changes Everything

The "Drug Affinity Complex" designation isn't marketing language. It describes a specific chemical modification at the C-terminus of the peptide: an N-epsilon-maleimidopropionyl-Lysine residue that binds reversibly to serum albumin after injection. Wikipedia 2025 Albumin is the most abundant plasma protein in circulation, and hijacking it as a carrier molecule extends the peptide's effective half-life from under 30 minutes to 5.8–8.1 days.

That half-life figure comes from the Teichman et al. 2006 Phase I/II trial, a double-blind, placebo-controlled study in healthy adults aged 21–61. A single injection produced dose-dependent increases in mean plasma GH concentrations of 2–10-fold lasting 6 days or more, and IGF-1 increases of 1.5–3-fold persisting for 9–11 days. Teichman et al. 2006

After multiple doses, mean IGF-1 levels remained above baseline for up to 28 days. Teichman et al. 2006 This cumulative effect is the clinical basis for weekly dosing protocols: you're not just dosing once per week out of convenience, you're leveraging genuine pharmacokinetic accumulation.

What DAC Does to Your GH Pulse Architecture

Ionescu and Frohman (2006) demonstrated that sustained CJC-1295 stimulation raises basal (trough) GH levels approximately 7.5-fold while preserving natural pulse frequency and magnitude. Peptide Catalog 2026 The analogy is a rising tide: your individual GH pulses still occur, but they ride on an elevated baseline rather than dropping back to near-zero between secretory events.

The trade-off is that continuous GHRH receptor stimulation raises theoretical concerns about pulsatility feedback blunting over time. Revolution Health 2025 There's also evidence that some subjects experience elevated cortisol and prolactin with DAC variants that isn't observed with no-DAC. Peptide Deck 2026 These aren't deal-breakers, but they're relevant selection criteria covered below.

CJC-1295 No-DAC: The Pulsatile Alternative

CJC-1295 no-DAC (also sold as Modified GRF 1-29 or Mod GRF 1-29) is the 29-amino acid GHRH analogue without the albumin-binding modification. Its half-life is approximately 30 minutes. Wikipedia 2025 That means each injection produces a discrete GH pulse that clears within 1–2 hours, closely mimicking the pattern of endogenous hypothalamic GHRH release.

This pulsatile architecture is its primary clinical argument. Natural GH secretion is episodic: large pulses at sleep onset, smaller pulses throughout the day, with clear troughs between them. Those troughs are not dead time; they're part of the receptor sensitivity reset that prevents downregulation. Revolution Health 2025

The no-DAC variant preserves this architecture. The consequence is that you inject daily (or twice daily in advanced protocols) rather than weekly, which increases injection burden but maintains physiologic hormonal rhythms. Peptide Dosages 2026

CJC-1295 DAC Dosage Protocol

Standard Dosing Range

The standard CJC-1295 DAC protocol derived from research and clinical practice is 2 mg (2,000 mcg) once weekly via subcutaneous injection. Peptide Dosages 2026 Some protocols place this at 1–2 mg once weekly, with the lower end appropriate for first-time users assessing tolerability.

The Teichman et al. trial used weight-based dosing of 30–60 mcg/kg, which for an 80 kg male translates to approximately 2,400–4,800 mcg. Clinical practice has largely standardised on 2 mg flat-dose for practical and economic reasons, which sits at or below the lower end of trial dosing for most adult males.

Reconstitution

For a standard 2 mg vial: add 1.0 mL of bacteriostatic water to yield a concentration of 2.0 mg/mL. Each 0.1 mL (10 IU on an insulin syringe) equals 200 mcg; a full 1.0 mL draw equals the full 2 mg weekly dose. Always inject bacteriostatic water along the vial wall, not directly onto the lyophilised cake. Swirl; do not shake.

Injection Timing for DAC

Because CJC-1295 DAC produces sustained elevation rather than acute pulses, timing is less critical than with no-DAC. Most protocols recommend morning or evening subcutaneous injection into abdominal or lateral deltoid fat. Consistency of day matters more than time of day; pick a day and stick to it to maintain even plasma levels through the accumulation phase.

Steady-State Timeline

Steady-state IGF-1 elevation takes approximately 2–3 weeks of consistent weekly dosing to establish. Wikipedia 2025 Don't assess efficacy or adjust dose before week 3. Most protocols run 8–12 weeks before a planned off-cycle.

CJC-1295 No-DAC Dosage Protocol: Loading and Maintenance

Loading Phase (Weeks 1–6)

Begin at 100 mcg per injection, once daily. This conservative entry point allows you to assess tolerability, particularly injection-site reactions and the transient flushing some users experience in the first 30–60 minutes post-injection. Peptide Dosages 2026

Increase by approximately 50 mcg every 1–2 weeks based on tolerance. A standard loading progression looks like this:

• Week 1: 100 mcg daily
• Week 2–3: 150 mcg daily
• Week 4–5: 200 mcg daily
• Week 6+: 250–300 mcg daily (maintenance target)

The clinical perfect-b protocol for combined no-DAC + Ipamorelin starts at 0.6 mg daily in week 1, escalating by roughly 2 units per week to reach a 2.0 mg maintenance dose by month 2. Perfect B 2026 That broader range reflects the combined stack rather than no-DAC alone.

Maintenance Phase

Target maintenance for most men 35+ researching GH axis optimisation is 200–300 mcg once daily, injected subcutaneously. Alpha Rejuvenation 2025 The 200 mcg figure is commonly cited as the effective threshold with the most favourable side-effect profile. Moving to 300 mcg produces marginally stronger GH pulses at the cost of higher incidence of water retention and transient headaches.

Injection Timing for No-DAC

Timing is critical here. Growth hormone releases its largest natural pulse during the first phase of deep sleep; injecting no-DAC 1–2 hours post-meal in the evening aligns the induced GH pulse with this endogenous window. Perfect B 2026 Insulin suppresses GH release, so a fasted or low-insulin state at injection time is mechanistically important. Avoid injecting within 90 minutes of a carbohydrate-heavy meal.

Weekly Schedule: 5-On, 2-Off

A 5-day-on, 2-day-off weekly schedule is preferred over continuous daily dosing. Alpha Rejuvenation 2025 The two rest days maintain GHRH receptor sensitivity by allowing partial resensitisation. Most practitioners use Saturday and Sunday as off days for practical adherence reasons, though any two consecutive days work equally well.

Stacking CJC-1295 No-DAC with Ipamorelin

The most commonly researched protocol pairs CJC-1295 no-DAC with Ipamorelin, a selective GH secretagogue that acts on the ghrelin receptor rather than the GHRH receptor. The rationale is synergy across two independent receptor pathways: GHRH receptor stimulation (CJC-1295) plus ghrelin receptor stimulation (Ipamorelin) produces 5–10 times the GH pulse magnitude compared to either compound alone. Peptide Catalog 2026

Ipamorelin's additional advantage: it selectively stimulates GH without elevating ACTH or cortisol. Perfect B 2026 This cleaner hormonal profile makes it the preferred partner for no-DAC protocols where avoiding cortisol elevation is a priority.

Combined Stack Dosing

Both peptides are dosed at equal amounts at the same injection time:

• Loading: 100 mcg CJC-1295 no-DAC + 100 mcg Ipamorelin, increasing by 50 mcg each every 1–2 weeks
• Maintenance: 200–300 mcg of each, once daily, evening, fasted state
• Schedule: 5 days on, 2 days off per week; 12–16 weeks on, 4–6 weeks off per quarter

For more detail on the synergistic mechanisms and protocol structure, see our in-depth guide on CJC-1295 + Ipamorelin synergistic dosing.

Cycling Protocols: Why the Off-Phase Matters

Continuous GHRH receptor stimulation without rest periods carries a real risk of receptor desensitisation and pituitary downregulation. Alpha Rejuvenation 2025 This isn't theoretical; it's the mechanism behind why exogenous GH secretagogues lose effectiveness over multi-month continuous use without structured breaks.

Two cycling frameworks appear consistently across clinical practice:

• Conservative: 60–90 days on, 30 days off. Revolution Health 2025
• Aggressive: 12–16 weeks on, 4–6 weeks off. Alpha Rejuvenation 2025

During the off-phase, some protocols use MK-677 (an oral ghrelin mimetic) to maintain IGF-1 elevation via a mechanistically distinct receptor pathway, avoiding GHRH receptor fatigue while retaining some metabolic continuity. Revolution Health 2025 This is a reasonable strategy for men seeking uninterrupted GH axis support, though MK-677 has its own considerations around insulin sensitivity and water retention.

For a detailed breakdown of the pituitary physiology behind cycling decisions, read our guide on pituitary downregulation and receptor cycling.

DAC vs No-DAC: Which Variant Is Right for You?

This decision comes down to three variables: injection compliance, desired GH secretion architecture, and side-effect profile preference.

Choose CJC-1295 DAC if:

• You want the simplicity of once-weekly dosing
• Your primary goal is sustained IGF-1 elevation for body composition and recovery
• Daily injections are logistically difficult to maintain
• You're comfortable with elevated baseline GH rather than pulsatile spikes

Choose CJC-1295 No-DAC if:

• You want to preserve natural pulsatile GH architecture
• You're stacking with Ipamorelin and want the cleanest possible combined hormonal profile
• Cortisol and prolactin management is a priority
• You prefer shorter side-effect duration (if they occur, they clear with the 30-minute half-life)

Neither variant is categorically superior. The DAC version has more direct human trial data from Teichman et al. 2006. The no-DAC variant's pulsatile profile has mechanistic support from GHRH physiology and is preferred in clinical practice when stacking. LIVV Natural 2025

Reconstitution and Storage

Correct reconstitution preserves peptide integrity. Errors here degrade your compound before it ever reaches a syringe.

CJC-1295 DAC (2 mg vial): Add 1.0 mL bacteriostatic water along the vial wall. Concentration: 2.0 mg/mL. Each 0.1 mL draw = 200 mcg.

CJC-1295 No-DAC (5 mg vial): Add 3.0 mL bacteriostatic water. Concentration: approximately 1.67 mg/mL. Each 0.1 mL draw = 167 mcg; adjust volume accordingly for your target dose.

Storage: Store lyophilised (dry powder) at or below -20°C, away from light and moisture. After reconstitution, refrigerate at 2–8°C and use within 30–45 days. Never freeze reconstituted peptide and avoid repeated freeze-thaw cycles, which degrade the molecule rapidly.

Full reconstitution technique, injection site rotation, and stability guidance is covered in the reconstitution, storage, and stability reference guide.

Safety Profile and Side Effects

The Teichman et al. 2006 Phase I/II trial demonstrated that CJC-1295 was safe and relatively well tolerated at doses of 30–60 mcg/kg, without notable adverse effects. Peptides.org 2024

The FDA regulatory submission covering the 192-patient HIV lipodystrophy trial identified the most common side effects as: flu-like symptoms, headaches, irritability, anxiety, nausea, and hives. FDA Submission 2006

Across trial data, incidence rates break down as follows: BiohackNow 2025

• Injection-site reactions (pain, redness, swelling): approximately 70% of participants
• Transient headaches: approximately 60%
• Diarrhoea: approximately 40%
• Flushing, mild water retention, insomnia: reported but less quantified

No serious adverse events were reported in healthy adult populations at research dosing ranges. One subject death in the HIV lipodystrophy trial was attributed to pre-existing coronary artery disease and judged unrelated to treatment. FDA Submission 2006

The Long-Term Safety Gap

This is the honest limitation of the current literature: no peer-reviewed human trial has evaluated CJC-1295 safety beyond 90 days of continuous administration. Real Peptides 2026 The longest published study ran 13 weeks across 47 subjects with no serious events, but IGF-1 elevation of 1.5–2.5x baseline persisted throughout. Sustained supraphysiologic IGF-1 has theoretical implications for tissue growth signalling that have not been characterised in long-term human trials.

Practical mitigation: monitor IGF-1, fasting glucose, and lipids every 4–6 weeks. Structure on-off cycles as outlined above. Work with a qualified clinician who can interpret these biomarkers in context.

Mitigation Strategies

• Rotate injection sites (abdomen, lateral thigh, deltoid fat) to reduce local reactions
• Titrate dose gradually during loading to identify personal tolerance threshold
• Stay well hydrated; many transient side effects (headaches, flushing) are attenuated by adequate hydration
• With no-DAC, transient side effects resolve within 1–2 hours as the compound clears; with DAC, side effects may persist longer given the extended half-life

CJC-1295 vs Comparator Compounds

CJC-1295 sits within a broader GHRH analogue landscape. Key comparisons:

Tesamorelin: The 44-amino acid GHRH analogue with FDA approval for HIV-associated lipodystrophy. Shorter half-life than CJC-1295 DAC but more clinical trial data and regulatory precedent. The better-documented choice for visceral fat reduction specifically. See our Tesamorelin comparison and alternatives guide for the full breakdown.

Sermorelin: The original 29-amino acid GHRH fragment with an 11–12 minute half-life. Less potent and shorter-acting than CJC-1295 no-DAC; used primarily in older anti-ageing protocols before CJC-1295 became more widely available.

Exogenous HGH: Bypasses the pituitary entirely and delivers GH directly. Stronger suppression of endogenous GH production; different risk profile. CJC-1295 works upstream via GHRH stimulation, preserving pituitary involvement.

Monitoring Markers During a CJC-1295 Protocol

Baseline bloodwork before starting any CJC-1295 protocol should include: IGF-1, fasting insulin, fasting glucose, HbA1c, lipid panel, and a comprehensive metabolic panel. This gives you a reference point and catches any pre-existing conditions that would change risk calculus.

During the protocol, retest IGF-1 every 4–6 weeks. The target is elevation above your personal baseline without exceeding the upper quartile of the age-adjusted reference range. Supraphysiologic IGF-1 sustained over months is the variable with the most theoretical long-term risk; it's also the most actionable lab value for dose adjustment decisions. Always work with a qualified clinician before making changes to your health protocol.

Quick-Reference Dosage Table

Bibliography

• Teichman SL et al. (2006). Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting GHRH analogue, in healthy adults. J Clin Endocrinol Metab.
• Alba M et al. (2006). Once-daily administration of CJC-1295 normalizes growth in GHRH knockout mouse. Am J Physiol Endocrinol Metab.
• FDA Regulatory Submission (2006). CJC-1295 Safety Summary by James LaValle RPh CCN.
• Real Peptides (2026). Is CJC-1295 Safe for Long Term Use? Research Insights.
• BiohackNow Longevity Clinic (2025). CJC-1295 Side Effects and How to Mitigate Them.
• Alpha Rejuvenation (2025). CJC-1295 Ipamorelin Dosage Protocol.
• Revolution Health and Wellness (2025). Why You Should Cycle CJC-1295 and Tesamorelin.

This content is for educational purposes only. These compounds are intended for research use. Nothing here is medical advice. Always work with a qualified clinician before making changes to your health protocol.